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Abstract
Background: Food allergy diagnosis in clinical studies can be challenging. Oral food 
challenges (OFC) are time-consuming, carry some risk and may, therefore, not be ac-
ceptable to all study participants.
Objective: To design and evaluate an algorithm for detecting IgE-mediated food al-
lergy in clinical study participants who do not undergo OFC.
Methods: An algorithm for trial participants in the Barrier Enhancement for Eczema 
Prevention (BEEP) study who were unwilling or unable to attend OFC was developed. 
BEEP is a pragmatic, multi-centre, randomized-controlled trial of daily emollient for 
the first year of life for primary prevention of eczema and food allergy in high-risk 
infants (ISRCTN21528841). We built on the European iFAAM consensus guidance 
to develop a novel food allergy diagnosis algorithm using available information on 
previous allergenic food ingestion, food reaction(s) and sensitization status. This was 
implemented by a panel of food allergy experts blind to treatment allocation and 
OFC outcome. We then evaluated the algorithm's performance in both BEEP and 
Enquiring About Tolerance (EAT) study participants who did undergo OFC.
Results: In 31/69 (45%) BEEP and 44/55 (80%) EAT study control group participants 
who had an OFC the panel felt confident enough to categorize children as “prob-
able food allergy” or “probable no food allergy”. Algorithm-derived panel decisions 
showed high sensitivity 94% (95%CI 68, 100) BEEP; 90% (95%CI 72, 97) EAT and 
moderate specificity 67% (95%CI 39, 87) BEEP; 67% (95%CI 39, 87) EAT. Sensitivity 
and specificity were similar when all BEEP and EAT participants with OFC outcome 
were included.
Conclusion: We describe a new algorithm with high sensitivity for IgE-mediated food 
allergy in clinical study participants who do not undergo OFC.
Clinical Relevance: This may be a useful tool for excluding food allergy in future clini-
cal studies where OFC is not conducted.
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1  | INTRODUC TION
Food allergy affects approximately 5% of young children and has a 
significant quality of life and economic impact.1-3 The gold standard 
for diagnosing food allergy in clinical studies is a double-blind, pla-
cebo-controlled oral food challenge (OFC).4 However, open (non-
blinded) OFC are widely used for detection of food allergy in young 
children, where placebo-controlled challenges may be impractical 
and the reporting of subjective symptoms less likely.5 Recent guid-
ance from the European iFAAM (Integrated approaches to Food 
Allergen and Allergy risk Management) project provides a frame-
work for when to undertake OFC in clinical studies where food al-
lergy is an end-point.6 This guidance suggests that if a food has been 
eaten without symptoms of allergy, or if a food has not been eaten, 
but there is no evidence of allergic sensitization, then OFC is not 
required. However, the guidance does not specify more precisely the 
frequency, form and quantity of food ingestion that is sufficient to 
exclude allergy, or which symptoms related to ingestion indicate an 
allergic reaction. Importantly, the guidance does not address detec-
tion of food allergy where OFC is not completed. Hence, there is a 
need for a more detailed and complete algorithm to guide food al-
lergy diagnosis within clinical studies, especially those where uptake 
of OFC by study participants is low.
The Barrier Enhancement for Eczema Prevention (BEEP) 
study is a pragmatic, multi-centre, randomized-controlled trial of 
daily emollient use for the first year of life for primary preven-
tion of eczema, in infants with a family history of atopic disease 
(ISRCTN21528841). Evaluation of IgE-mediated food allergy was 
added to the initial study protocol after recruitment had com-
menced, but before any 2-year follow-up visits were conducted, 
once separate funding was secured.7 It was anticipated that a sig-
nificant number of participants might decline to attend for OFC in 
BEEP, as the food allergy testing was presented to parents at the 
2-year visit as an optional sub-study in a pragmatic, low-contact 
trial with eczema prevention as its initial focus. Furthermore, the 
BEEP trial was a multi-centre trial run across a wide geographical 
area and study OFCs were limited to two UK centres, Sheffield 
and London (See map of geographical distribution of recruited in-
dividuals in Supinfo 2). In the EuroPrevall UK birth cohort study, 
based on a similar-aged population, over 30% of parents offered 
OFC to cow's milk declined attendance.8 We, therefore, devel-
oped an algorithm for use in the BEEP study which aims to reli-
ably diagnose IgE-mediated food allergy. We then validated the 
algorithm in BEEP study participants who had undergone OFC 
and separately in participants from the control group (standard 
introduction group) of another intervention trial, Enquiring About 
Tolerance (EAT; ISRCTN14254740), who had undergone OFC and 
had a similar set of information available about allergenic food ex-
posure, reactions and sensitization status.
2  | METHODS
We evaluated food allergy outcomes in the BEEP study, which pre-
sented an opportunity to develop a new approach to food allergy 
diagnosis in clinical research studies with expected low uptake of 
OFC. We then validated our findings in BEEP study participants who 
had undergone OFC and in participants from the control group of 
the EAT study who had undergone OFC.
2.1 | BEEP study design
The BEEP study is a pragmatic, parallel-group, multi-centre, as-
sessor-blind, randomized-controlled trial, details of which have 
been described elsewhere.7 In brief, the BEEP study randomized 
1395 participants between November 2014 and November 2016, 
recruited from 16 study centres across England. Participants 
were born at ≥37-week gestation and had a first-degree relative 
with parent-reported eczema, asthma or allergic rhinitis diagno-
sis. They were randomized within 3 weeks of birth to apply daily 
emollient for 12 months plus skin care advice, or skin care advice 
only. Written informed consent was obtained at screening, prior 
to randomization, either during pregnancy or within 21 days of 
birth. Separate written consent was obtained at the 2-year visit 
for skin prick testing (SPT) and additional consent was obtained if 
OFC was required.
2.2 | BEEP study food allergy evaluation
Formal evaluation for the point prevalence of IgE-mediated food 
allergy, using a combination of food allergy history, SPT and 
OFC, in accordance with iFAAM guidance, was conducted at the 
primary outcome assessment visit at age 2 years. All BEEP par-
ticipants were offered SPT at these visits, usually conducted in 
the home unless parents preferred a clinic visit. Peanut extract 
(Inmunotek), fresh whole cow's milk, and fresh raw hen's egg white 
were tested, with positive (1% histamine) and negative (0.9% sa-
line) controls (Allergopharma). OFC was offered if the participant 
had a positive SPT and was not a frequent consumer of relevant 
forms of milk, egg or peanut; or if they had a positive SPT and a 
reported reaction to one of the foods (Figure 1). Open OFCs were 
conducted by experienced allergy nurses in recognized paediatric 
allergy centres (Sheffield Children's Hospital and Imperial College 
London), following standard operating procedures modified 
from the European Academy of Asthma and Clinical Immunology 
PRACTicals of ALLergy (PRACTALL) consensus. Fresh whole 
cow's milk, raw hen's egg white (red lion stamped, salmonella free) 
and peanut butter (Sunpat, Histon Sweet Spreads Ltd) or ground 
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peanut flour (Golden peanut company) were used for OFC.9 All 
study staff remained blinded to treatment allocation. The pres-
ence of a clinical reaction during OFC was determined using modi-
fied PRACTALL criteria (See Supinfo 1).4
2.2.1 | Elaboration of iFAAM guidance
iFAAM guidance suggests OFC is not indicated in clinical trials if (A) 
the food is eaten without out symptoms or (B) the food has not been 
eaten but the participant is not sensitized. OFC is indicated if (C) the 
food is not eaten but the participant is sensitized or (D) the food is 
eaten and a reaction has occurred.6 We first elaborated on these cri-
teria in order to more precisely define “sensitized”, “reaction”, “food” 
and “eating without reaction”.
For the definition of “sensitized”, we considered a participant to be 
“sensitized” when the skin prick test was any response (>0 mm), in order 
to maximize the sensitivity of our procedure.10 Though correlation be-
tween skin test response size and OFC outcome is dependent on the 
population studied, in general, SPT weal size correlates with probability 
of reacting at OFC, and in 2-year olds, a 7 mm response is considered 
strongly predictive for milk, egg or peanut allergy. Hence, we catego-
rized ≥7 mm as “strongly sensitized”.11 Values between 1 and 6 mm were 
considered “intermediate sensitization”. For those without SPT, we con-
sidered SpIgE to be negative if it had been done and <0.35 kUa/L.
For the definition of “reaction”, we considered any parent-re-
ported reactions to a food within 2 hours of exposure to be an “im-
mediate” reaction.
For the definition of “food”, we used the most allergenic form of 
food consumed in the local population. We considered milk and egg 
F I G U R E  1   Selection of study participants for invitation to oral food challenge
Parcipant; 
i. frequent and recent consumer of 
milk, runny egg and peanut ?
AND 
ii. Has no reported history of reacon 
within 2 h?
No Food Allergy to Milk, Egg, Peanut 
No OFC 
24 mo visit
Food consumpon and food allergy 
reacon history quesons. 
SPT undertaken if consent given. 
Parcipant; 
i. Not a Frequent and recent consumer 
of milk, runny egg and peanut ?
AND/OR
ii. has a reported history of reacon 
within 2 h?
SPT negave 
(0 mm) to all 
relevant food(s)
SPT posive 
(>0 mm) to any 
relevant food(s)
No SPT 
consent given
Possible Food Allergy to Milk, Egg, Peanut
Invite for OFC 
Allergy team in Sheffield or London 
invite child for OFC 
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allergy as allergy to any form of milk or egg, even if other forms such 
as baked or processed milk/egg were tolerated. We considered pea-
nut ingestion in any form to be relevant. We used fresh milk, raw egg 
white and commercial peanut extract for SPT.
For the definition of “eating without reaction”, we recorded par-
ent-reported ingestion. We adapted food frequency questionnaires 
from the EAT study, to identify frequent and recent ingestion of 
each food allergen.12 “Recent” ingestion was the food being ingested 
within 3 months of the 2-year interview for milk and egg; within 
1 month for peanut. The shorter duration for peanut is due to the 
possibility of new-onset peanut allergy in the second year. “Frequent 
consumption” was defined as three or more separate reported in-
gestions of two or more grams of relevant food protein, at any age.
2.3 | Food allergy diagnosis algorithm
We expected some participants would decline to attend OFC, due to 
an established diagnosis or unwillingness to travel to an OFC centre. 
To establish accurate food allergy status for these participants we 
convened an expert panel of experienced paediatric allergists (MK, 
NJ, MRP, RJB) to determine food allergy status whilst remaining 
blinded to treatment allocation. We developed the algorithm using 
an iterative process of discussion and consensus-building, involving 
the panel and the wider trial management group and trial steering 
committee. We did not use a formal Delphi or nominal group process. 
We referred to relevant literature and recent cohort studies or food 
allergy prevention trials in developing the algorithm and modified 
some data collection materials and processes from the BASELINE 
cohort study and EAT prevention trial.12,13 The panel used all avail-
able information from the study procedures to guide their decision-
making (Table 1). Through repeated revisiting of all cases of possible 
food allergy within BEEP, we developed a consensus-based approach 
to diagnosing IgE-mediated food allergy to milk, egg or peanut in a 
setting where participants did not undergo OFC.
2.4 | Validation of food allergy diagnosis algorithm
Having developed the algorithm using information from BEEP study 
participants who did not have an OFC, we then compared algorithm-
derived expert panel decision-making with OFC outcome in (i). BEEP 
study participants who underwent OFC; and (ii). EAT study, stand-
ard introduction group, participants who underwent OFC. Validation 
was conducted with panel blinding to food challenge outcomes and 
was conducted separately for each dataset.
EAT is a randomized trial of 1303 exclusively breastfed 3-month 
old infants that compared introduction of six allergenic foods from 
age 3 months with advice to continue exclusive breastfeeding to 
age 6 months.12 The EAT data set (ITN900AD) is available through 
TrialShare, a public Web site managed by the Immune Tolerance 
Network (www.itntr ialsh are.org). Primary outcome of the trial was 
IgE-mediated food allergy evaluated by OFC. In the EAT study, at 
36 months, all children in both standard and early introduction 
groups who had a positive SPT (≥1 mm) to a study food were offered 
OFC. “Frequent consumers” of the food underwent a challenge reg-
imen with less doses.
We established algorithm-derived panel diagnoses for partici-
pants in both trials with an OFC outcome. Panel assessments were 
undertaken by the same four paediatric allergists, blind to OFC out-
come. For EAT, we only used standard introduction group partic-
ipants since the intervention involved a change to allergenic food 
exposure which is part of the algorithm and was associated with 
reduced food allergy in EAT. Sensitivities and specificities were cal-
culated for the detection of IgE-mediated food allergy in BEEP and 
EAT separately.
Source BEEP study EAT study
Study Questionnaires Food ingestion–recentness and 
frequency
Food ingestion–form and 
frequency
Reported reaction–age, form 
of food, symtoms, timing of 
symptoms
Reported reaction–age, form 
of food and symptoms
Study Investigations Skin prick testing to fresh milk, 
raw egg and commercial peanut 
extract
Skin prick test to fresh milk, 
raw egg and commercial 
peanut extract
Other Health Care 
Provider Information
Correspondence from any 
assessments in a paediatric 
allergy clinic prior to BEEP study 
OFC
No
OFC Protocol Fresh cow's milk Semi skimmed milk powder.
Raw egg white Pasteurized raw egg powder 
(DBPCFC) or boiled egg 
(open challenges).
Peanut butter or peanut flour Peanut butter or Bamba
Total 4.43 g food protein Total 5.3 g food protein
TA B L E  1   Study-specific information 
used in algorithm-derived panel decisions 
and OFC procedures
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F I G U R E  2   Algorithm for classifying food allergy where oral food challenge is requested but not conducted
IMMEDIATE-TYPE REACTION?
Parent-reported clinical reacon within 2 h of eang the food ever?
STRONGLY SENSITISED?
i.e. Posive skin prick test ≥7 mm 
OR 
No skin prick test done, and high 
level specific IgE from local clinic
STRONGLY SENSITISED?
i.e. Posive skin prick test ≥7 mm 
OR 
No skin prick test done, and high 
level specific IgE from local clinic
NO
NO
CLEAR ALLERGIC REACTION(S)?
Repeated (≥2) reacons, or reacons consistent** 
with an IgE-mediated allergy?
YES
YES
NO
No Food Allergy Unclear 
PARTIAL CLINICAL TOLERANCE?
Evidence that food has been tolerated repeatedly or 
recently – 1 or 2 exposures close to the ED50*** for that 
food; OR mulple smaller exposures
YES
NO
NOYES
PARTIAL CLINICAL TOLERANCE?
Evidence that food has been 
tolerated repeatedly or recently – 1 
or 2 exposures close to the 
ED50*** for that food; OR mulple 
smaller exposures
Probable food 
allergy 
YES
NO
Unclear – food 
allergy possible 
Unclear – food 
allergy unlikely 
ytivitisneS an
al
ys
is 
e
moctuo
doof
yra
mirP
RECENT SPT 0 mm?*
At study visit or using similar allergens, procedures 
and trained personnel to the BEEP study 
No food allergy 
Probable food 
allergy
NO
MORE LIKELY THAN OTHER PARTICIPANTS TO HAVE A 
FOOD ALLERGY TO THIS FOOD? 
History of a possible reacon within 2 h, posive skin 
prick test of SpIgE, AND no repeated recent tolerance of the 
food.  
YES
YES
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3  | RESULTS
3.1 | Algorithm development
3.1.1 | Algorithm for diagnosis of food allergy where 
OFC cannot be completed
The final algorithm is shown in Figure 2. The algorithm was devel-
oped by an expert allergy panel blind to treatment allocation. Those 
with negative SPT are deemed not food allergic. If SPT was not com-
pleted in the trial but was completed in a local clinical service using 
the same form of allergen and standard procedures, the result is con-
sidered by the panel. If SPT is positive or missing the panel considers 
reaction history. Likelihood of allergy is considered lower for less 
consistent, less frequent reactions, or reactions without typical IgE-
mediated features.3,14 Where possible, grams of protein ingested 
can be calculated, based on review of ingredient lists of relevant 
foods, to identify whether relevant quantities have been ingested 
without reaction.
For participants not “eating without reaction”, diet history is used 
to evaluate “probable tolerance” based on consumption of the ED 50 
(eliciting dose at which 50% of allergic individuals react), or multi-
ple exposures of lesser quantities, without reaction. Likelihood of 
allergy is lowest where parents reported larger, more unadulterated, 
frequent and recent asymptomatic food consumption. Presence of 
other doctor-diagnosed IgE-mediated food allergies is also be con-
sidered by the panel, where relevant, given the increased likelihood 
of a second food allergy.
Eczema history was not taken into consideration in develop-
ing this algorithm, since eczema prevalence may be modified by an 
emollient intervention such that use of eczema history to categorize 
food allergy could introduce a bias in food allergy outcome assess-
ments in BEEP in favour of the study intervention. However, timing 
and severity of eczema could be used in other settings to inform 
algorithm-derived panel decision-making.15
For classification of overall food allergy status, the food with the 
highest hierarchical determined food allergy outcome is used; that is, if 
a participant has OFC confirmed egg allergy but has “probable” peanut 
allergy they are classed as having OFC confirmed food allergy.
We include a demographic table of those children who did not 
undergo oral food challenge and who had their food allergy status 
classified through this algorithm in the Supinfo 1.
3.1.2 | Algorithm approach for participants who are 
sensitized with immediate-type reaction
Reported immediate-type reaction and strong sensitization on SPT 
(≥7 mm) is “probable food allergy”. If SPT data are missing, high-level 
SpIgE results in the same classification. For immediate-type reactions 
without strong sensitization, reaction symptoms are considered first. 
If the reaction is reproducible (occurred twice or more) and typical of 
an IgE-mediated reaction (eg acute urticaria, angioedema, vomiting, 
cough/wheeze settling within hours) participants have “probable food 
allergy”. If reaction history is less clear, without strong sensitization, 
the precise quantity and frequency of allergen previously tolerated is 
considered. If the participant has evidence of subsequent sufficient ex-
posure without reaction they are labelled “no food allergy”, if there is 
no evidence of sufficient exposure they are labelled “unclear”.
3.1.3 | Algorithm approach for participants who are 
sensitized with no immediate reaction
For participants with positive SPT who have not recently and fre-
quently eaten the food allergen, the panel considers the SPT level. For 
those “strongly sensitized” (≥7 mm), the quantity and frequency of al-
lergen previously tolerated are next considered, looking for evidence 
of partial clinical tolerance. Consumption at the ED50 or multiple ex-
posures to smaller doses is evidence of clinical tolerance. Participants 
strongly sensitized by SPT with no evidence of partial clinical tolerance 
have “probable food allergy”. Participants strongly sensitized by SPT 
with evidence of partial clinical tolerance are labelled “unclear”. For 
participants who are not strongly sensitized (SPT < 7 mm), evidence of 
Food SPT result Comments Panel decision
Milk 8.5 mm More than two reactions in infancy within 
30 min of exposure, currently strictly avoiding 
all milk products.
Probable milk 
allergy
Peanut 5.5 mm Confirmed egg allergy. Never ingested peanut. Unclear–
possible 
peanut allergy
Egg No SPT Never exposed to whole egg or runny egg. 
Tolerates baked egg in cakes.
Unclear–egg 
allergy 
unlikely
Milk 2 mm Gastrointestinal symptoms within 30 min of 
milk exposure during infancy. Now tolerates 
at least 100 mL cow's milk (lactose free) daily, 
without symptoms.
No food allergy
Abbreviation: SPT, skin prick test.
TA B L E  2   Examples of case 
classification by algorithm-derived panel 
consensus
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partial tolerance is again considered—there is “no food allergy”, if par-
tial tolerance criteria are met, and “unclear” food allergy status if not.
Examples of panel decision-making using anonymized BEEP 
study participants are shown in Table 2.
3.1.4 | Classification of participants with “unclear” 
food allergy status
Participants with “unclear” food allergy status cannot be reliably clas-
sified by the panel, but we undertook a sensitivity analysis where 
“unclear” participants were classified by the panel. They were catego-
rized as “unclear–food allergy possible” where there was a history of 
reaction, a history of doctor-diagnosed food allergy to another food, 
or other features to suggest increased probability of food allergy com-
pared with the rest of the study population. “Unclear–food allergy un-
likely” status was given to participants where there was no information 
to suggest any increased risk of food allergy over the rest of the study 
population, including participants with significant missing data.
3.2 | Algorithm validation
3.2.1 | Comparison of algorithm-derived panel 
decisions with OFC outcomes from BEEP and 
EAT studies
In 31/69 (45%) BEEP and 44/55 (80%) EAT study control group par-
ticipants who had an OFC the panel were able to classify partici-
pants as “probable food allergy” or “probable no food allergy”. For 
these participants, algorithm-derived panel decisions showed high 
sensitivity 94% (95%CI 68, 100) in BEEP, 90% (95%CI 72, 97) in EAT; 
and moderate specificity 67% (95%CI 39, 87) in BEEP, 67% (95%CI 
39, 87) in EAT. Other participants could not be confidently classified 
due to missing information about ingestion or reaction history or 
sensitization status. The available information was considered, and 
they were classified as “unclear–food allergy possible” and “unclear–
food allergy unlikely” based on available information. Sensitivity and 
specificity were broadly similar when participants with “unclear” 
food allergy status were included in the analysis (Table 3).
4  | DISCUSSION
Making a robust food allergy diagnosis in clinical studies using the 
gold standard of OFC can be time-consuming, sometimes unpleas-
ant and potentially risky for study participants.16 Some studies are 
not resourced to undertake OFC to all potential food allergens and 
OFC may be declined by participants, carers or investigators or even 
considered unethical where participants are already known to have 
a firm diagnosis of IgE-mediated food allergy. While some studies 
have successfully confirmed the diagnosis of food allergy using OFC 
in up to 90% of cases5,12,17 others have been less successful and T
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for pragmatic trials or those where food allergy is not the primary 
outcome measure then surrogates for OFC may be required. We, 
therefore, developed and evaluated a specific, algorithm-guided 
approach for detecting IgE-mediated food allergy as an outcome in 
clinical studies. We built on previous guidance for the diagnosis of 
food allergy using a combination of clinical information and, where 
available, specific allergy diagnostic.6 Our algorithm-guided expert 
panel approach demonstrated high sensitivity, reliably detecting 
food allergy when present; but only moderate specificity, suggesting 
that our approach may misclassify some study participants without 
food allergy as “food allergic”.
In both BEEP and EAT, there was often a time-lag between ques-
tionnaire responses at 24 and 36 months, and subsequent OFC. For 
egg and milk allergy which are in the process of resolving over the 
first couple of years, this could account for some cases where algo-
rithm-derived panel diagnosis based on information from the 24 or 
36 month visit suggested “food allergy”, but OFC found no food al-
lergy. Variations in allergen formulation in SPT and OFC could also im-
pact on accuracy of the algorithm. For example, in EAT raw egg white 
was used for SPT but a mixture of both whole egg powder (for the dou-
ble-blind component) and boiled egg (for the open component) was 
used for OFC. Although the panel took this information into consider-
ation when making algorithm-derived decisions, the discrepancy be-
tween materials used in SPT and OFC may introduce some inaccuracy.
Algorithm-based diagnosis has been used by others in a clinical 
context for food allergy diagnosis, both with and without compre-
hensive information on sensitization status.18,19 Our findings in a 
clinical research setting at a homogenous, defined age, complement 
this prior work and build on the guidance from the iFAAM project, 
but would need separate validation before use in a clinical context.
This algorithm was also developed in the context of an eczema 
prevention trial, so that eczema could not be used within the algo-
rithm, despite being a major predictor of food allergy risk. Future 
iterations of this algorithm may consider including timing of eczema 
onset and eczema severity as variables to be considered by the panel 
in their decision-making. Algorithm development using formal Delphi 
consensus or nominal group techniques may also have higher validity.
Finally, aside from our algorithm development, in BEEP we have 
confirmed in a clinical trial of 1395 infants that SPT can be safely 
conducted at home, by appropriately trained and equipped person-
nel. We favoured SPT over SpIgE for detection of sensitization, due 
to the better sensitivity and specificity of SPT for food allergy diag-
nosis in young children.20 This approach, therefore, remains to be 
validated in clinical studies which rely on SpIgE without SPT testing 
for foods.
In conclusion, we have described the development and evalua-
tion of a new algorithm for the diagnosis of IgE-mediated food al-
lergy in clinical studies of young children. This may be a useful tool 
for excluding food allergy in study participants who do not attend an 
OFC. We cannot recommend our algorithm in replacement of OFC 
since it only has moderate specificity, but the algorithm reliably ex-
cludes food allergy and is, therefore, likely to be a useful supplement 
to OFC in future clinical studies.
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